Thierry Alcindor
Thierry Alcindor
Verified email at
Cited by
Cited by
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
Oxaliplatin: a review in the era of molecularly targeted therapy
T Alcindor, N Beauger
Current oncology 18 (1), 18-25, 2011
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ...
The Lancet Oncology 20 (10), e566-e581, 2019
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients …
GD Demetri, SP Chawla, I Ray-Coquard, A Le Cesne, AP Staddon, ...
Journal of Clinical Oncology 31 (19), 2485-2492, 2013
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ...
The Lancet 394 (10197), 478-487, 2019
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre …
WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ...
The lancet oncology 18 (8), 1089-1103, 2017
Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial
N Pavlakis, KM Sjoquist, AJ Martin, E Tsobanis, S Yip, YK Kang, YJ Bang, ...
Journal of Clinical Oncology 34 (23), 2728, 2016
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
B Melosky, R Burkes, D Rayson, T Alcindor, N Shear, M Lacouture
Current oncology 16 (1), 16-26, 2009
PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma
CW Ryan, O Merimsky, M Agulnik, JY Blay, SM Schuetze, BA Van Tine, ...
Journal of Clinical Oncology 34 (32), 3898-3905, 2016
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease
T Alcindor, G Gorgun, KB Miller, TF Roberts, K Sprague, DP Schenkein, ...
Blood, The Journal of the American Society of Hematology 98 (5), 1622-1625, 2001
European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of …
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
Lancet Oncol 15 (4), 415-423, 2014
Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine
GD Demetri, P Schöffski, G Grignani, JY Blay, RG Maki, BA Van Tine, ...
Journal of Clinical Oncology 35 (30), 3433-3439, 2017
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial
LE Ferri, S Ades, T Alcindor, M Chasen, V Marcus, M Hickeson, G Artho, ...
Annals of oncology 23 (6), 1512-1517, 2012
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial
DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ...
The lancet oncology 21 (8), 1066-1076, 2020
Sideroblastic anaemias
T Alcindor, KR Bridges
British journal of haematology 116 (4), 733-743, 2002
EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
A Paliga, R Onerheim, A Gologan, G Chong, A Spatz, T Niazi, A Garant, ...
British journal of cancer 107 (11), 1864-1868, 2012
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a …
HJ Mackay, HJ Au, E McWhirter, T Alcindor, A Jarvi, K MacAlpine, L Wang, ...
Investigational new drugs 30 (3), 1158-1163, 2012
Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis
LE French, T Alcindor, M Shapiro, KS McGinnis, DJ Margolis, D Porter, ...
Bone marrow transplantation 30 (8), 509-515, 2002
INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian …
N Pavlakis, KM Sjoquist, E Tsobanis, AJ Martin, YK Kang, YJ Bang, ...
Journal of Clinical Oncology 33 (15_suppl), 4003-4003, 2015
The system can't perform the operation now. Try again later.
Articles 1–20